Deutsche Bank raised the firm’s price target on Eli Lilly to $695 from $535 and keeps a Hold rating on the shares. The analyst updated the company’s model post the Q4 report.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LLY:
- Foghorn Therapeutics says Lilly selects FHD-909 for clinical development
- Eli Lilly price target raised to $865 from $710 at BMO Capital
- Eli Lilly price target raised to $850 from $650 at Truist
- Amgen downgraded to Market Perform from Outperform at Leerink
- Eli Lilly price target raised to $825 from $700 at Wells Fargo